Bristol-Myers Squibb Reports Positive Phase 3 SCOUT-HCM Results for Camzyos in Adolescent Patients

Bristol-Myers Squibb Company (NYSE:BMY) is one of the cheap S&P 500 stocks to invest in now. On January 12, Bristol-Myers ...

Will Positive Data on Camzyos Strengthen BMY's Cardiovascular Portfolio?

BMY reports positive late-stage data for Camzyos in adolescents with oHCM, expanding its cardiovascular outlook amid pipeline ...
Pharmabiz

Bristol Myers Squibb reports positive results from phase 3 SCOUT-HCM trial of Camzyos in adolescents with symptomatic oHCM

Princeton, New Jersey Wednesday, January 14, 2026, 12:00 Hrs [IST] ...
The Cardiology Advisor

Mavacamten Significantly Improves Symptomatic oHCM in Adolescent Population

SCOUT-HCM findings show mavacamten significantly reduces Valsalva LVOT gradient in adolescents with symptomatic oHCM.
eLife

Secreted exosomes induce filopodia formation

Exosome-associated THSD7A is identified as a key trigger of filopodia formation in cancer cells and neurons, revealing a novel pathway with implications for metastasis, neuronal connectivity, and ...